On January 18 2018 Health Canada and the Institute for Safe Medication Practices Canada opened their consultation on different approaches to the naming of biologic drugs, including biosimilars (for further details please see "Biosimilars update").
The consultation's aim is to gain insight into stakeholder views on the practical impacts of different approaches to the naming of biologic drugs and biosimilars throughout the medication use process, including:
- prescribing;
- dispensing; and
- adverse drug reaction reporting.
Stakeholder views on the aforementioned topics will inform Health Canada's ultimate policy decision on the naming convention for biologic drugs.
For further information on this topic please contact Urszula Wojtyra at Smart & Biggar/Fetherstonhaugh by telephone (+1 416 593 5514) or email ([email protected]). The Smart & Biggar/Fetherstonhaugh website can be accessed at www.smart-biggar.ca.
This article was first published by the International Law Office, a premium online legal update service for major companies and law firms worldwide. Register for a free subscription.
